• O. M. Oleshchuk I. Horbachevsky Ternopil state medical university, Ukraine
  • H. Ya. Loi I. Horbachevsky Ternopil state medical university, Ukraine




lleptine resistance, type 2 diabetes, metformin.


Leptin is one of adipocyte-secreted hormones. It signals to the brain and other tissues about the status of body energy reserves. Circulating leptin levels are directly proportional to the amount of the body fat. Leptin concentration increases when surfeit and decreases during fasting. Obese patients are hyperleptinemic compared with thin persons and they are tolerant to the central hypothalamic effects of leptin. The reduced sensitivity toward exogenous and endogenous leptin is commonly referred to as leptin resistance. Alterations in the signaling of the long isoform of the leptin receptor play the crucial role in leptin resistance. Surfeit may induce leptin resistance and other metabolic sequelae of obesity. Leptin insensitivity and insulin resistance play a major role in the development of type 2 diabetes. Metformin remains the preferred first-line pharmacologic agent for the treatment of type 2 diabetes. It reduces hepatic glucose production, increases glucose uptake in peripheral tissue and can lead to weight loss. Metformin decreases both insulin and leptin concentration, restores the sensitivity to these hormones. But some studies have shown poor relationship between metformin action and leptin level. And the mechanism of metformin action on leptin resistance remains unclear. Thus, these issues should be studied as well as polymorphisms in genes encoding metformin action.

Author Biography

H. Ya. Loi, I. Horbachevsky Ternopil state medical university, Ukraine

PhD student of pharmacology with clinical pharmacology


Kershaw E, Flier J. Adipose tissue as an endocrine organ. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2548–2556.

Bluher S, Mantzoros C. Leptin in humans: lessons from translational research. The American journal of clinical nutrition. 2009;89(3):991–997.

Leibel RL. Molecular physiology of weight regulation in mice and humans. International Journal of Obesity. 2008;32:98–108.

De Luis DA, Castrillon JL Perez, Duenas A. Leptin and obesity. Minerva medical J. 2009;100(3):229 –236.

Considine R. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine. 1996;334(5):292 –295.

Unger R. Lipotoxic diseases. Annual review of medicine. 2002;53(1):319–336.

Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. The Journal of Clinical Endocrinology & Metabolism. 1996;81(9):3419–23.

Houseknecht KL, Baile CA, Matteri RL, Spurlock ME. The biology of leptin: a review. Journal of Animal Science. 1998;76(5):1405–20.

Zhang Y, Scarpace PJ. The role of leptin in leptin resistance and obesity. Physiology & behavior. 2006;88(3):249–56.

Prieur X, Tung YL, Griffin JL, Farooqi IS, O'Rahilly S, Coll AP. Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology. 2008;149(11):5432–9.

Cohen MM. Role of leptin in regulating appetite, neuroendocrine function, and bone remodeling. American Journal of Medical Genetics. Part A. 2006;140(5):515–24.

Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, Palladino G, Donini A, Ricci P, Fiorucci S. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6(7):229–78.

Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, Witters LA, Unger RH. PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proceedings of the National Academy of Sciences. 2002;99(18):11848–53.

Seufert J. Leptin effects on pancreatic β-cell gene expression and function. Diabetes. 2004;53:152–8.

Muhlhausler BS, Morrison JL, McMillen IC. Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-γ target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation. Endocrinology. 2009;150(9):4287–94.

Gallardo N, Bonzon-Kulichenko E, Fernandez-Agullo T, Molto E, Gomez-Alonso S, Blanco P, Carrascosa JM, Ros M, Andres A. Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology. 2007;148(12):5604–10.

Caprio M, Fabbrini E, Isidori AM, Aversa A, Fabbri A. Leptin in reproduction. Trends in Endocrinology & Metabolism. 2001;12(2):65–72.

Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. The Journal of Clinical Endocrinology & Metabolism. 2006;91(7):2605–11.

Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clinical endocrinology. 2006;64(4):355–65.

Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116(2):337–50.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425.

Muller TD, Focker M, Holtkamp K, Herpertz-Dahlmann B, Hebebrand J. Leptin-mediated neuroendocrine alterations in anorexia nervosa: somatic and behavioral implications. Child and adolescent psychiatric clinics of North America. 2009;18(1):117–29.

Leshan RL, Björnholm M, Münzberg H, Myers MG. Leptin receptor signaling and action in the central nervous system. Obesity. 2006;14(8):208–12.

Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.

Ahima RS, Prabakaran D, Mantzoros C, Qu D. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382(6588):250.

Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897–901.

Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. The Journal of clinical investigation. 2003;111(9):1409–21.

Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, Gallagher D, Mayer L, Murphy E, Leibel RL. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. The Journal of clinical investigation. 2005;115(12):3579–86.

Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocrine reviews. 2013;34(3):377–412.

Gray SL, Donald C, Jetha A, Covey SD, Kieffer TJ. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic β-cell leptin signaling. Endocrinology. 2010;151(9):4178–86.

Maedler K, Schulthess FT, Bielman C, Berney T, Bonny C, Prentki M, Donath MY, Roduit R. Glucose and leptin induce apoptosis in human β-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases. The FASEB Journal. 2008;22(6):1905–13.

Miras M, Ochetti M, Martín S, Silvano L, Sobrero G, Castro L, Onassis M, de Talamoni NT, Perez A, Picotto G, de Barboza GD. Serum levels of adiponectin and leptin in children born small for gestational age: relation to insulin sensitivity parameters. Journal of Pediatric Endocrinology and Metabolism. 2010;23(5):463–71.

Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends in Endocrinology & Metabolism. 2004 Oct 31;15(8):362–9.

Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR, Wenner BR, Bain JR, Charron MJ, Newgard CB, Unger RH. Leptin therapy in insulin-deficient type I diabetes. Proceedings of the National Academy of Sciences. 2010;107(11):4813–9.

Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proceedings of the National Academy of Sciences. 2010 ;107(37):16009–12.

Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proceedings of the National Academy of Sciences. 2008;105(37):14070–5.

Kondo H, Shimomura I, Matsukawa Y, Kumada M, Takahashi M, Matsuda M, Ouchi N, Kihara S, Kawamoto T, Sumitsuji S, Funahashi T. Association of adiponectin mutation with type 2 diabetes. Diabetes. 2002;51(7):2325–8.

Saito K, Takashi TO, Madoka YO, NAKANO Y, Nam-Ho CM, TOMITA M. Regulation of gelatin-binding protein 28 (GBP28) gene expression by C/EBP. Biological and Pharmaceutical Bulletin. 1999;22(11):1158–62.

Kiess W, Petzold S, Topfer M, Garten A, Blüher S, Kapellen T, Körner A, Kratzsch J. Adipocytes and adipose tissue. Best Practice & Research Clinical Endocrinology & Metabolism. 2008;22(1):135–53.

Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology—emerging clinical applications. Nature Reviews Endocrinology. 2006;2(6):318–27.

Widdowson PS, Upton R, Buckingham R, Arch J, Williams G. Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes. 1997;46(11):1782–5.

Shek EW, Scarpace PJ. Resistance to the anorexic and thermogenic effects of centrally administrated leptin in obese aged rats. Regulatory peptides. 2000;92(1):65–71.

Munzberg H. Differential leptin access into the brain—a hierarchical organization of hypothalamic leptin target sites. Physiology & behavior. 2008;94(5):664–9.

Saad M, Pettitt D, Mott D, Knowler W, Nelson R, Bennett P. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. The Lancet. 1989;333(8651):1356–9.

Wang J, Obici S, Morgan K, Barzilai N, Feng Z, Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes. 2001;50(12):2786–91.

World Health Organization: Fact Sheet No.311.2012. www.who.int/mediacentre/factsheets/fs311/en/. Accessed May 2012.

Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JC, Fruhbeck G. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obesity facts. 2015;8(3):166–74.

International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care Jan 2017; 40 (Supplement 1):11–24.

Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. International journal of obesity. 2002;26(3):425.

Upadhyaya P, Rehan HS, Seth V. Serum leptin changes with metformin treatment in polycystic ovarian syndrome: correlation with ovulation, insulin and testosterone levels. EXCLI journal. 2011;10–9.

Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. The Journal of clinical investigation. 2002;110(8):1093–103.

Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor by nuclear receptors. Diabetes. 2003;52(7):1655–63.

Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes. 1996;45(11):1455–63.

Igel M, Becker W, Herberg L, Joost HG. Hyperleptinemia, Leptin Resistance, and Polymorphic Leptin Receptor in the New Zealand Obese Mouse 1. Endocrinology. 1997;138(10):4234–9.

Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nature medicine. 1995;1(12):1311–4.

Wang J, Liu R, Liu L, Chowdhury R, Barzilai N, Tan J, Rossetti L. The effect of leptin on Lep expression is tissue-specific and nutritionally regulated. Nature medicine. 1999;5(8):895–9.

Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763–70.

Surwit RS, Petro AE, Parekh P, Collins S. Low plasma leptin in response to dietary fat in diabetes-and obesity-prone mice. Diabetes. 1997;46(9):1516–20.

Flier, Jeffrey S. Leptin expression and action: new experimental paradigms. Proceedings of the National Academy of Sciences .1997; 94(9):4242–4245.

Ravussin E, Pratley RE, Maffei M, Wang H, Friedman JM, Bennett PH, Bogardus C. Relatively low plasma leptin concentrations precede weight gain in Pima Indians. Nature medicine. 1997;3(2):238–40.

American Diabetes Association. Standards of Medical Care in Diabetes–2017 Abridged for Primary Care Providers. Clinical Diabetes. 2017;35(1):5–26.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. Jama. 2016;316(3):313–24.

Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063–9.

Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes. 2008;57(1):24–31.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140–9.

Kay JP, Alemzadeh R, Langley G, D'angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50(12):1457–61.

Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50(7):856-61.

Fruehwald-Schultes B, Oltmanns KM, Toschek B, Sopke S, Kern W, Born J, Fehm HL, Peters A. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism. 2002;51(4):531–6.

Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. 2011;60(3):327–34.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation. 2001;108(8):1167–74.

Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002;51(8):2420–5.

Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339–43.

Klein J, Westphal S, Kraus D, Meier B, Perwitz N, Ott V, Fasshauer M, Klein HH. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. Journal of endocrinology. 2004;183(2):299–307.

Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH. Metformin restores leptin sensitivity in high-fat–fed obese rats with leptin resistance. Diabetes. 2006;55(3):716–24.

Kim YW, Choi DW, Park YH, Huh JY, Won KC, Choi KH, Park SY, Kim JY, Lee SK. Leptin-like effects of MTII are augmented in MSG-obese rats. Regulatory peptides. 2005;127(1):63–70.

Fruehwald-Schultes B, Oltmanns KM, Toschek B, Sopke S, Kern W, Born J, Fehm HL, Peters A. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism. 2002;51(4):531–6.

Guler S, Gürsoy G, Serter R, Aral Y. Leptin concentrations are related to glycaemic control, but do not change with short‐term oral antidiabetic therapy in female patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2000;2(5):313–6.

Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News. 2007;145:52.

Pasechko NV, Oleshchuk OM, Loi GY. Рharmacogenetic Aspects of Metformin Action in Patients with Type 2 Diabetes Mellitus. International Journal of Endocrinology. 2016;8(80):66-72.

Leptin (150-167) (Human). 2016. http://www.chemicalbook.com/ProductChemicalPropertiesCB3304602_EN.htm. Accessed 2016.




How to Cite

Oleshchuk, O. M., & Loi, H. Y. (2017). LEPTIN RESISTANCE AND TYPE 2 DIABETES. International Journal of Medicine and Medical Research, 3(1), 15–21. https://doi.org/10.11603/ijmmr.2413-6077.2017.1.7563